Quick NICE blessing for Daiichi's VTE drug after EU approval
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal body for England and Wales, has recommended Daiichi Sankyo's venous thromboembolism (VTE) therapy Lixiana (edoxaban) less than a month after European regulatory approval was granted for the product.